Novogen Ltd - Report of Foreign Issuer (6-K)
June 27 2008 - 6:02AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
______________________________________________
Form
6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER
THE
SECURITIES
EXCHANGE ACT OF 1934
For the
month of June, 2008
Commission
File Number
________________
Novogen
Limited
(Translation
of registrant’s name into English)
140 Wicks
Road, North Ryde, NSW, Australia
(Address
of principal executive office)
___________________________________
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form 20-F
x
Form 40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(l):
o
Note:
Regulation S-T Rule 101 (b)( I) only permits the submission in paper of a Form
6-K if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule lO1(b)(7):
o
Note:
Regulation S-T Rule l01(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant’s “home country”), or under the rules of the home country exchange on
which the registrant’s securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant’s security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule l2g3-2(b) under the Securities Exchange Act of 1934. Yes
o
No
x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf
by the undersigned, thereunto duly
authorized.
Novogen
Limited
(Registrant)
/s/ Ron
Erratt
Ronald
Lea Erratt
Company
Secretary
Date
26 June, 2008
ASX
& MEDIA RELEASE
26
JUNE, 2008
MARSHALL
EDWARDS, INC. JOINS RUSSELL 3000
®
INDEX
Novogen
Limited’s subsidiary, Marshall Edwards Inc., (NASDAQ: MSHL), has made the
following announcement:
NEW
CANAAN, CONNECTICUT - 26 June, 2008 —Marshall Edwards, Inc. (NASDAQ: MSHL), a
clinical-stage biotechnology company developing a new class of oncology drugs
known as “multi-signal transduction regulators,” today announced that it is soon
to be included in the Russell 3000® Index, according to a preliminary list of
additions recently posted on
www.russell.com
. Marshall
Edwards, Inc.’s addition to the broad market Russell 3000 Index, which remains
in place for one year, means automatic inclusion in the Russell 2000®
Index. The 2008 reconstitution of the Russell indexes will take place
after the market closes on June 27, 2008.
“With our
lead drug candidate phenoxodiol in a pivotal phase III trial for recurrent
ovarian cancer, the Russell 3000 Index has recognised our potential,” said
Christopher Naughton, President and Chief Executive
Officer. “Marshall Edwards, Inc.’s inclusion in the Russell 3000
Index offers us visibility to more investors.”
The
Russell 3000 Index measures the performance of the largest 3,000 US companies
based on total market capitalisation, representing approximately 98% of the
investable US equity market according to Russell Investments. The
Russell 2000 Index is a subset of the Russell 3000 Index representing
approximately 10% of the total Market capitalisation of that index and includes
approximately 2,000 of the smallest securities based on a combination of their
market capitalisation and current index membership in the Russell 3000
Index.
About
phenoxodiol:
Phenoxodiol
is being developed as a chemosensitising agent in combination with platinum
drugs for late stage, chemoresistant ovarian cancer and as a monotherapy for
prostate and cervical cancers. It has a unique mechanism of action,
binding to cancer cells via a cell membrane oxidase, causing major downstream
disturbances in expression of proteins necessary for cancer cell survival and
responsible for the development of drug resistance.
In cancer
cells, phenoxodiol appears to selectively inhibit the regulator known as S-1-P
(sphingosine-1-phosphate) that is over-expressed in cancer cells. In
response to phenoxodiol, the S-1-P content in cancer cells is decreased, with a
consequent decrease in expression of the pro-survival proteins XIAP and FLIP,
rendering those cells more sensitive to chemotherapy. Indeed, in
laboratory studies, it has been demonstrated that drug-resistant ovarian cancer
cells pre-treated with phenoxodiol were killed with lower doses of chemotherapy
drugs.
Importantly,
phenoxodiol has been shown not to adversely affect normal cells in animal and
laboratory testing.
Phenoxodiol
is being investigated as a therapy for late-stage, chemoresistant ovarian,
prostate and cervical cancers. Phenoxodiol has received Fast Track
status from the FDA to facilitate its development as a therapy for recurrent
ovarian and prostate cancers.
Phenoxodiol
is an investigational drug and, as such, is not commercially
available. Under US law, a new drug cannot be marketed until it has
been investigated in clinical trials and approved by FDA as being safe and
effective for the intended use.
Phenoxodiol
is the first of a family of compounds in the Marshall Edwards, Inc. drug
pipeline of flavonoid derivatives.
About
Marshall Edwards, Inc:
Marshall
Edwards, Inc. is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics. These derive from a
flavonoid technology platform, which has generated a number of novel compounds
characterised by broad ranging activity against a range of cancer cell types
with few side effects. The combination of anti-tumour cell activity
and low toxicity is believed to be a result of the ability of these compounds to
target an enzyme present in the cell membrane of cancer cells, thereby
inhibiting the production of pro-survival proteins within the
cell. Marshall Edwards, Inc. has licensed rights from Novogen Limited
(ASX:NRT Nasdaq: NVGN) to bring three oncology drugs -- phenoxodiol,
triphendiol and NV-143 -- to market globally. The Company's lead
investigational drug, phenoxodiol, is in a Phase III multinational multi-centred
clinical trial for patients with recurrent ovarian cancer. More
information on the trial can be found at
http://www.OVATUREtrial.com
.
Marshall
Edwards, Inc. is majority owned by Novogen Limited (ASX:NRT NASDAQ: NVGN), an
Australian biotechnology company that is specialising in the development of
therapeutics based on a flavonoid technology platform. Novogen is developing a
range of therapeutics across the fields of oncology, cardiovascular disease and
inflammatory diseases. More information on phenoxodiol and on the
Novogen group of companies can be found at
www.marshalledwardsinc.com
and
www.novogen.com
.
Under US.
law, a new drug cannot be marketed until it has been investigated in clinical
trials and approved by the FDA as being safe and effective for the intended use.
Statements included in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. You should be aware
that our actual results could differ materially from those contained in the
forward-looking statements, which are based on management's current expectations
and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates;
costs and delays in the development and/or FDA approval, or the failure to
obtain such approval, of our product candidates; uncertainties in clinical trial
results; our inability to maintain or enter into, and the risks resulting from
our dependence upon, collaboration or contractual arrangements necessary for the
development, manufacture, commercialization, marketing, sales and distribution
of any products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice; and
one-time events. We do not intend to update any of these factors or to publicly
announce the results of any revisions to these forward-looking
statements.
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024